Isoprenaline is a synthetic, non-selective agonist of beta-adrenergic receptor and is used for the treatment of bradycardia, heart block, and congestive heart failure.

Isoprenaline is a synthetic, non-selective agonist of beta-adrenergic receptor and is used for the treatment of bradycardia, heart block, and congestive heart failure.

Isoprenaline is a synthetic, non-selective agonist of beta-adrenergic receptor and is used for the treatment of bradycardia, heart block, and congestive heart failure.

Ribociclib succinate hydrate is an orally bioavailable and selective, inhibitor of both CDK4 and CDK6 with IC50 values of 10 nM and 39 nM, respectively. It exhibits anticancer activitiy and can be used in breast cancer, melanoma, liposarcoma, non–small cell lung cancer, and neuroblastoma therapy research.

Ribociclib succinate hydrate is an orally bioavailable and selective, inhibitor of both CDK4 and CDK6 with IC50 values of 10 nM and 39 nM, respectively. It exhibits anticancer activitiy and can be used in breast cancer, melanoma, liposarcoma, non–small cell lung cancer, and neuroblastoma therapy research.

Ribociclib succinate hydrate is an orally bioavailable and selective, inhibitor of both CDK4 and CDK6 with IC50 values of 10 nM and 39 nM, respectively. It exhibits anticancer activitiy and can be used in breast cancer, melanoma, liposarcoma, non–small cell lung cancer, and neuroblastoma therapy research.

Ribociclib succinate hydrate is an orally bioavailable and selective, inhibitor of both CDK4 and CDK6 with IC50 values of 10 nM and 39 nM, respectively. It exhibits anticancer activitiy and can be used in breast cancer, melanoma, liposarcoma, non–small cell lung cancer, and neuroblastoma therapy research.

Alpelisib hydrochloride is a potent and selective inhibitor of PI3Kα with an IC50 of 0.005 μM, 1.2 μM, 0.29 μM, 0.25 μM for p110α, p110β, p110δ, p110γ, respectively. It exhibits good efficacy in inhibiting the growth of PI3Ka driven tumors and can be used in cancer research.